Q&A Translational Cancer Nanomedicine.
Where this comes from
- Record sourced from PubMed, PMID 40957878.
- Also identified by DOI 10.1038/s41467-025-63488-x and PMC identifier 12441112.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The preclinical exploration of nanomedicine for cancer theranostics is rapidly expanding, underscoring its significant translational potential. The diverse physicochemical properties of these nanosystems — including size, morphology, surface charge, hydrophobicity, catalytic activity, and chirality — inevitably influence their interactions with biological systems. As a result, comprehensive biological validation and interdisciplinary collaboration across fields such as biochemistry, biomedical engineering, pharmacology, immunology, and oncology are essential.